NASDAQ:XNCR Xencor (XNCR) Stock Price, News & Analysis $21.65 +0.38 (+1.79%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$21.33▼$22.3950-Day Range$18.18▼$24.5052-Week Range$16.49▼$26.84Volume422,342 shsAverage Volume649,871 shsMarket Capitalization$1.33 billionP/E RatioN/ADividend YieldN/APrice Target$35.38 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Xencor alerts: Email Address Xencor MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside63.4% Upside$35.38 Price TargetShort InterestBearish7.77% of Shares Sold ShortDividend StrengthN/ASustainability-2.24Upright™ Environmental ScoreNews Sentiment1.11Based on 4 Articles This WeekInsider TradingSelling Shares$665,547 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.50) to ($3.07) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.06 out of 5 starsMedical Sector199th out of 936 stocksPharmaceutical Preparations Industry82nd out of 436 stocks 3.5 Analyst's Opinion Consensus RatingXencor has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageXencor has only been the subject of 4 research reports in the past 90 days.Read more about Xencor's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted7.77% of the outstanding shares of Xencor have been sold short.Short Interest Ratio / Days to CoverXencor has a short interest ratio ("days to cover") of 8.Change versus previous monthShort interest in Xencor has recently decreased by 0.83%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldXencor does not currently pay a dividend.Dividend GrowthXencor does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreXencor has received a 53.56% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for infectious diseases", "Tafasitamab", and "Ravulizumab" products. See details.Environmental SustainabilityThe Environmental Impact score for Xencor is -2.24. Previous Next 4.0 News and Social Media Coverage News SentimentXencor has a news sentiment score of 1.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Xencor this week, compared to 2 articles on an average week.Search Interest2 people have searched for XNCR on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows4 people have added Xencor to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Xencor insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $665,547.00 in company stock.Percentage Held by InsidersOnly 5.23% of the stock of Xencor is held by insiders.Read more about Xencor's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Xencor are expected to grow in the coming year, from ($3.50) to ($3.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Xencor is -9.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Xencor is -9.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXencor has a P/B Ratio of 1.97. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Xencor's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Xencor Stock (NASDAQ:XNCR)Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.Read More XNCR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart XNCR Stock News HeadlinesJuly 12, 2024 | insidertrades.comXencor, Inc. (NASDAQ:XNCR) VP John R. Desjarlais Sells 36,329 SharesJuly 18, 2024 | americanbankingnews.comXencor, Inc. (NASDAQ:XNCR) Receives Average Rating of "Buy" from BrokeragesJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.June 13, 2024 | businesswire.comXencor Regains CD20 x CD3 Bispecific T-Cell EngagerMay 14, 2024 | markets.businessinsider.comBuy Rating Affirmed for Xencor: Strong Q1 Financials, FDA Approval, and Promising Pipeline Signal Growth PotentialMay 12, 2024 | markets.businessinsider.comBuy Rating Affirmed for Xencor on Strategic Focus and Strong Financial PositionMay 11, 2024 | finance.yahoo.comXencor First Quarter 2024 Earnings: Misses ExpectationsMay 10, 2024 | markets.businessinsider.comDecoding 6 Analyst Evaluations For XencorJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 10, 2024 | markets.businessinsider.comPiper Sandler Keeps Their Hold Rating on Xencor (XNCR)May 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Xencor on Strong Pipeline and Financials: Anticipated IND Filing and T-cell Engager DevelopmentsMay 10, 2024 | finance.yahoo.comXencor Inc (XNCR) Q1 2024 Earnings: Misses Revenue and Earnings EstimatesMay 10, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Sangamo Biosciences (SGMO), Xencor (XNCR) and Evolent Health (EVH)May 10, 2024 | investorplace.comXNCR Stock Earnings: Xencor Misses EPS, Misses Revenue for Q1 2024May 9, 2024 | businesswire.comXencor Reports First Quarter 2024 Financial ResultsMay 3, 2024 | finance.yahoo.comInsider Sale at Xencor Inc (XNCR): EVP, Chief Development Officer Nancy Valente Sells SharesApril 16, 2024 | markets.businessinsider.comAnalyst Scoreboard: 6 Ratings For XencorApril 11, 2024 | uk.investing.comXencor names Bart Cornelissen as new CFOSee More Headlines Receive XNCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xencor and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:XNCR CUSIPN/A CIK1326732 Webwww.xencor.com Phone(626) 305-5900Fax626-305-0350Employees280Year FoundedN/APrice Target and Rating Average Stock Price Target$35.38 High Stock Price Target$50.00 Low Stock Price Target$24.00 Potential Upside/Downside+63.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($2.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-126,090,000.00 Net Margins-82.23% Pretax Margin-79.16% Return on Equity-20.29% Return on Assets-15.72% Debt Debt-to-Equity Ratio0.02 Current Ratio7.08 Quick Ratio7.08 Sales & Book Value Annual Sales$168.34 million Price / Sales7.93 Cash FlowN/A Price / Cash FlowN/A Book Value$10.99 per share Price / Book1.97Miscellaneous Outstanding Shares61,660,000Free Float58,438,000Market Cap$1.33 billion OptionableOptionable Beta0.69 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. Bassil I. Dahiyat Ph.D. (Age 54)Co-Founder, CEO, President & Director Comp: $1.07MDr. John R. Desjarlais Ph.D. (Age 60)Executive VP of Research & Chief Scientific Officer Comp: $748.65kMs. Celia E. Eckert J.D. (Age 51)Senior VP, General Counsel & Corporate Secretary Comp: $641.85kDr. Nancy Valente M.D. (Age 65)Executive VP & Chief Development Officer Comp: $797.68kMr. Bart Jan CornelissenSenior VP & CFOMr. Charles LilesAssociate Director and Head of Corporate Communications & Investor RelationsMs. Jennifer SandozSenior VIce President of Human ResourcesDr. Jeremy Grunstein Ph.D.Senior Vice President of Business DevelopmentMr. Kirk Rosemark RAC (Age 59)Senior Vice President of Regulatory Affairs & Quality Assurance Mr. Eric P. KowackSenior Vice President of Program Leadership & Alliance ManagementMore ExecutivesKey CompetitorsKura OncologyNASDAQ:KURAZymeworksNYSE:ZYMEMacroGenicsNASDAQ:MGNXPrelude TherapeuticsNASDAQ:PRLDAimmune TherapeuticsNASDAQ:AIMTView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 15,974 shares on 7/26/2024Ownership: 0.812%Baillie Gifford & Co.Bought 744 shares on 7/25/2024Ownership: 0.038%Louisiana State Employees Retirement SystemBought 900 shares on 7/24/2024Ownership: 0.050%Diversified Trust CoBought 1,017 shares on 7/16/2024Ownership: 0.023%SG Americas Securities LLCBought 8,130 shares on 7/12/2024Ownership: 0.013%View All Insider TransactionsView All Institutional Transactions XNCR Stock Analysis - Frequently Asked Questions How have XNCR shares performed this year? Xencor's stock was trading at $21.23 at the beginning of the year. Since then, XNCR stock has increased by 2.0% and is now trading at $21.65. View the best growth stocks for 2024 here. How were Xencor's earnings last quarter? Xencor, Inc. (NASDAQ:XNCR) released its quarterly earnings results on Thursday, May, 9th. The biopharmaceutical company reported ($1.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.83) by $0.28. Xencor's revenue for the quarter was down 32.3% on a year-over-year basis. What is Bassil I. Dahiyat's approval rating as Xencor's CEO? 6 employees have rated Xencor Chief Executive Officer Bassil I. Dahiyat on Glassdoor.com. Bassil I. Dahiyat has an approval rating of 81% among the company's employees. Who are Xencor's major shareholders? Xencor's top institutional investors include Bank of New York Mellon Corp (0.81%), Linden Thomas Advisory Services LLC (0.07%), Louisiana State Employees Retirement System (0.05%) and Baillie Gifford & Co. (0.04%). Insiders that own company stock include Bassil I Dahiyat, John R Desjarlais, John J Kuch, Allen Yang, Celia Eckert and Kurt A Gustafson. View institutional ownership trends. How do I buy shares of Xencor? Shares of XNCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Xencor own? Based on aggregate information from My MarketBeat watchlists, some other companies that Xencor investors own include Intelsat (I), Bank of America (BAC), Apollo Global Management (APO), Cypress Semiconductor (CY), NVIDIA (NVDA), AbbVie (ABBV) and Exelixis (EXEL). This page (NASDAQ:XNCR) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xencor, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xencor With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
